natgillin/translations-raw huggingface dataset:
The preparation according to claim 7, characterised by that said other polysaccharide is carboxymethyl-B-1,3(1,6)-D-glucan having the molecular weight within the range of 1 000 to 1 500 000 g/mol and the substitution degree within the range of 0.05 to 3 expressed as the total amount of carboxymethyl groups to the total amount of monosaccharide units, and being in its free form or in the form of a pharmacologically suitable salt which is a sodium, potassium, lithium, calcium, magnesium, zinc, cobalt, manganese salt or another salt or a mixture thereof. 
Pripravak prema zahtjevu 7, naznačen time da je navedeni drugi polisaharid karboksimetil-f-1,3(1,6)-D-glukan koji ima molekularnu težinu u rasponu od 1 000 do 1 500 000 g/mol i stupanj supstitucije u rasponu od 0.05 do 3 izraženo kao ukupna količina karboksimetilnih skupina prema ukupnoj količini monosaharidnih jedinica, te je u slobodnom obliku ili u obliku farmakološki pogodne soli koja je natrijeva, kalijeva, litijeva, kalcijeva, magnezijeva, cinkova, kobaltova, sol mangana ili druga sol ili njihova smjesa. HR P20130387 T1
Pharmaceutical composition comprising 0.01 mg to 0.9 mg of aleglitazar or a salt thereof obtainable by 
Farmaceutski sastav, naznačen time, da sadrži 0,01 mg do 0,9 mg aleglitazara ili njegove soli, koji se dobiva pomoću:
Selenite at a concentration ranging from about 0.01 to about 0.012 mg/L, most preferably about 0.0110 mg/L. 
-Selenit u koncentraciji u rasponu od oko 0,01 do oko 0,012 mg/L, najpoželjnije oko 0.0110 mg/L.
The method of claim 5, wherein the ectoparasite is selected from the group consisting of Ctenocephalides, Rhipicephalus, Dermacentor, Ixodes, Boophilus, Ambylomma, Hyalomma, Sarcoptes, Psoroptes, Otodectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Hematopinus, Solenoptes and mixtures thereof. 
Tekuća injektibilna formulacija s produljenim djelovanjem za uporabu prema zahtjevu 8, naznačena time, da je ektoparazit odabran 12 skupine koju čine: Crenocephalides, Rhipicephalus, Dermacentor, Ixodes, Boophilus, Ambylomma, Hyalomma, Sarcoptes, Psoroptes, Otodectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Hematopinus, Solenoptes i njihove kombinacije.
The torpedo of claim 8, wherein the external heat source includes exhaust gasses from a motor. 
Torpedo prema zahtjevu 6, naznačen time da vanjski izvor topline uključuje dodavanje ispušnih plinova iz motora
The process according to any one of claims 7 to 16, characterized in that if all or part of the quantity of the at least one lithium ion-containing compound is added before dispersing step f), the at least one lithium ion-containing compound is added before and/or during and/or after grinding step d). 
Postupak u skladu s bilo kojim od patentnih zahtjeva 5do 14, karakteriziran na način da je sva ili dio količine barem jedne tvari koja sadrži litijev ion dodana prije koraka disperziranja f), barem jedna tvari koja sadrži litijev ion je dodana prije i/ili za vrijeme i/ili nakon koraka mljevenja d).
A diagnostic composition comprising a compound I a pharmaceutically acceptable carrier; 
Dijagnostički sastav obuhvaća tvar 1 [image] Tvar 1 farmaceutski prihvatljivi nosač;
independently represents a halogen atom or an alkyl group having from 1 to 2 carbon atoms; m is 0, 1 or 2; and 
neovisno predstavlja atom halogena ili alkilnu skupinu s 1 do 2 atoma ugljika; m je 0, 1 ili 2; i predstavlja
R1A is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid, and 
R! je odabran iz skupine koja sadrži vodik, po izboru supstituiran acil, po izboru supstituiranu O)-vezanu miksa, zA
The method of claim 8, wherein the outputting step further comprises outputting a set of rules concerning when the local IMSI is to be used by the subscribed device. 
Postupak prema zahtjevu 8, pri čemu izlazni korak dalje obuhvaća slanje skupa pravila koja se odnose na to kada je lokalni IMSI za upotrebu na pretplatničkom uređaju.
A peptide as claimed in claims 1 to 3, 6 or 7, wherein the peptide is formulated in a pharmaceutical composition for oral administration comprising coated citric acid particles, and wherein the coated citric acid particles increase the oral bioavailability of the peptide. 
Peptid za koji se traži zaštita u patentnim zahtjevima 1 do 3, 6 ili 7, pri čemu je peptid formuliran u farmaceutskom pripravku za oralnu primjenu koja sadrži obložene čestice limunske kiseline, i pri čemu obložene čestice limunske kiseline povećavaju oralnu biodostupnost peptida.
The compound for use of claim 1, or pharmaceutically acceptable salt thereof, wherein the disease is Parkinson's disease. 
Spoj za uporabu prema patentnom zahtjevu 4, pri čemu, hemolitička anemija je nasljedna ne-sferocitna hemolitička anemija.
It is furthermore preferred that the suspension of venlafaxine or the salt thereof in the solvent also comprises a binder. 
Nadalje je poželjno da suspenzija venlafaksina ili njegove soli u otapalu također sadrži vezivo.
Secondly, sexual dysfunction is generally a side effect common to SSRIs. 
Seksualna disfunkcija druga je popratna pojava kod uzimanja tog lijeka.
The method of item 2, wherein the other agent inhibits a molecule that promotes microtubule disassembly directly or indirectly. The method of item 2, wherein the other agent inhibits a molecule selected from the group consisting of ABP1, ARHGAP4. HSPA8, LCP1, PACSIN2, RUNX1T1, STMN1, and Tubulin, and TUBB4. 
Pripravak ili kombinacija za uporabu prema zahtjevima 1 do 3, gdje drugo sredstvo inhibira molekulu koja potiče rastavljanje mikrotubula izravno ili posredno. Pripravak ili kombinacija za uporabu prema zahtjevu 4, gdje drugo sredstvo inhibira molekulu odabranu iz skupine koju čine ABP1, ARHGAP4, HSPA8, LCP1, PACSIN2, RUNXITI, STMNI, i Tubulin, te TUBB4.
to 90 %, preferably 20-85% by weight of diluent, 
1 do 90 %, poželjnije 20-85 % masenog udjela razrjeđivača,
No. 5,613,958 to Kochinke et al.; and U.S. Patent No. 5,968,547 to Reder et al. Transdermal delivery systems of buprenorphine, made by Lohmann Therapie-Systeme GmbH & Co., are currently sold in the European Union under the trademark name TRANSTEC®. 
No. 5,613,958; te Reder et al., U. S. Patent No. 5,968,547. Sustavi transdermalnog davanja buprenorfina, izrađeni od strane Lohmann Therapie-Systeme GmbH & Co., trenuino se prodaju u Europskoj uniji pod žigom (trgovačkim nazivom) TRANSTECO.
A compound according to claim 1, wherein the compound of formula (Ia″) is a compound of formula (I-T2) 
Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (1a") su spojevi s formulom (I-T2)
The method of claim 7, wherein the solvent system has a water activity value of from 0.4 to 0.6. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što sustav otapala ima vrijednost aktiviteta vode od 0,4 do 0,6.
Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or haloalkyl; or Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which is optionally substituted with 1 to 2 groups each independently selected from halo, alkyl, haloalkyl, hydroxyl and alkoxy; and q is 0, 1 or 2. 
(i) svaki od R*i R"je neovisno vodik, alkil, alkenil, alkinil, cikloalkil ili halogenalkil; ili (ii) R*iR", zajedno s atomom dušika na kojeg su vezani, tvore heterociklil ili heteroaril koji je izborno supstituiran s 1 do 2 skupine, od kojh se svaku neovisno bira između halogena, alkila, halogenalkila, hidroksila i alkoksi; iqje0,1ili2.
A second observation from Figures 6, 7 and 8 is that the variability in the concentration of rapamycin, as demonstrated by the standard deviations shown on the graphs, was considerably lower for the rapamycin carbohydrate derivatives than for rapamycin itself. 
Iz slika 6, 7 i 8 još se može opaziti da je varijabilnost koncentracije rapamicina, kako je prikazano standardnim devijacijama prikazanim na grafovima, znatno manja za ugljikohidratne derivate rapamicina nego za sam rapamicin. HR P20070383 T3
An electrically heated smoking system according to claim 1, wherein the one or more electrically conductive tracks are on the inside of the tubular electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što jedna ili više električno vodljivih tračnica (203) se nalazi s unutrašnje strane cijevi od električno izolirajuće podloge (201).
each R6 independently is an optionally substituted aliphatic, aryl, or heteroaryl group; and 
svaki R5 je nezavisno vodik ili opcijski supstituirana alifatična, aril, heteroaril ili heterociklil grupa;
A spray dispenser according to claim 1, the dispensing assembly comprising a dispensing line, wherein the dispensing line is in a gas-tight sealing engagement with a dispensing line seal provider. 
Raspršivač sukladno bilo kojem prethodnom zahtjevu, sklop za točenje sadrži liniju za točenje, pri čemu je linija za točenje u nepropusnom spoju sa sredstvom za brtvljenje linije za točenje za plinove.
The compound of Claim 16 where R2 is -OH and R3 is H. 
Spoj u skladu s patentnim zahtjevom 16, naznačen time, da je R? je -OH i R? je H.
such that the functional movement restriction device can be completely invaginated by the stomach fundus of the human patient, and of at least 125 mm3, and a circumference of at least 15 mm. 
Uređaj u skladu s patentnim zahtjevom 2, naznačen time što je najmanje jedan od prvog i drugog međudjelujućeg elementa prilagođen da bude u najmanju ruku djelomično invaginiran stijenkom želuca međuželučanim kirurškim šavovima ili kopčama koji drže međudjelujući element na mjestu.
the term "alkoxy" indicates a straight or branched (C1-C4)alkoxy group; 
"alkoksi" jest ravna ili razgranata (C,-Cy)alkoksilna skupina;
The fusion protein, the immunogenic composition, or the vaccine of claims 1-19, 
Fuzijski protein, imunogeni pripravak, ili cjepivo u skladu s patentnim zahtjevima 1-19, naznačeni time što su
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. 
Prikladna zaštitna skupina za amino ili alkilamino skupinu je, na primjer acilna skupina, primjerice alkanoilna skupina poput acetila, alkoksikarbonila skupina, na primjer metoksikarbonilna, etoksikarbonilna ili t-butoksi-karbonilna skupina, arilmetoksikarbonilna skupina, na primjer benziloksikarbonil, ili aroilna skupina, na primjer benzoil.
Process according to claim 1, characterized in that the pump (1) is an electrical or a mechanical one. 
Uređaj prema zahtjevu 1, naznačen time da pumpa (1) je električna ili mehanička pumpa.
The surface of the enclosing member should preferably form, together with the capsule surface (rim portion) a wedge-like space such that the sealing member can be form of low dynamically to fill any place and/or gaps. 
Poželjno je da površina elementa koji obuhvaća čahuru tvori, zajedno s površinom čahure (predio ruba) prostor koji ima oblik klina, tako da element za brtvljenje može biti oblikovan s malom dinamičkom silom kako bi ispunio svaki prostor ifili sve pukotine.
A compound according to claim 35, wherein R9a is optionally substituted phenyl, preferably phenyl substituted with C1-C6alkyl; C1-C6alkoxy; or halo: 
Spoj u skladu sa zahtjevom 37, naznačen time, da R9a je po izboru supstituirani fenil, povoljno je fenil supstituiran s C1-C6alkil; C1-C6alkoksi; ili halo.
dissolving said precipitated phosphate compounds into a second leach solution, providing a feed solution comprising iron phosphates; 
otapanje (261) spomenutih istaloženih fosfatnih spojeva u drugu otopinu za ispiranje, čime se pruža (260) otopina za raspršivanje koja sadrži željezne fosfate;
A method according to claim 3, wherein also during step d) the basic amino acid or derivative thereof is present at a final concentration of at least 1 mM and is sufficient to prevent or reduce aggregation of the Enteroviral particles. 
Postupak prema patentnom zahtjevu 3, naznačen time što je 1 tijekom koraka d) bazna aminokiselina ili njezin derivat prisutan u finalnoj koncentraciji od najmanje 1 mM, i dovoljan je da spriječi ili smanji agregaciju enterovirusnih čestica.
as an isolated stereoisomer or a mixture thereof, or as a pharmaceutically acceptable salt thereof, wherein cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms having from three to fifteen carbon atoms; and 
kao izolirani stereoizomer ili njihova mješavina, ili kao njihova farmaceutski prihvatljiva sol, pri čemu se cikloalkil odnosi na stabilni nearomatski monociklički ili policiklički radikal ugljikovodika koji se sastoji isključivo od atoma ugljika i vodika koji ima od tri do petnaest atoma ugljika; i alkil se odnosi na ravni ili razgranati radikal lanca ugljikovodika koji se sastoji isključivo od atoma ugljika i vodika, nije nezasićen, te ima od jedan do dvanaest atoma ugljika.
The composition thus obtained has then the absolute purity as requested, it does not need any further purification and can be used as such for all indications and pharmaceutical and para-pharmaceutical formulations known in the prior art. 
Tako dobiveni pripravak ima zatim apsolutnu čistoću kao što se zahtijeva, ne treba nikakvo daljnje pročišćavanje i može se upotrijebiti kao takav za sve indikacije i farmaceutske i para-farmaceutske preparate poznate u prethodnom stanju tehnike.
The pharmaceutical or cosmetic composition according to claim 1, wherein the composition is selected from the group solid compositions, liquid compositions, solutions, emulsions, microemulsions, suspensions, and nasal sprays. 
Farmaceutski ili kozmetički pripravak prema zahtjevu 2, naznačen time, što je pripravak odabran iz grupe koja se sastoji od čvrstih pripravaka, tekućih pripravaka, otopina, emulzija, mikroemulzija, suspenzija, krema, losiona, gelova, prašaka i sprejeva za nos.
providing a high density polyethylene post consumer resin (PCR) having an ESCR (100%) of at most 10 hours as determined according to ASTM D 1693 (2013) condition B, a density ranging from 0.950 to 0.967 g/cm3 as determined according to ASTM 1505 at a temperature of 23°C, an HLMI of 40 to 70 g/10 min as determined according to ISO 1133, condition G, at 190°C and 21.6 kg; 
- < Pribava recikliranog polietilena visoke gustoće (PCR) sa ESCR (100%) od najviše 10 sati kako je utvrđeno prema ASTM D 1693 (2013), uvjet B, gustoćom u rasponu između 0.950 do 0.967 g/ems kako je utvrđeno prema ASTM 1505 na temperaturi od 23*C, HLMI od 40 do 70 g/10 min kako je utvrđeno prema ISO 1133, uvjet G, na 190% i 21.6kg;
flushing said composition by a flow of discharge water for cleaning and/or disinfecting and/or perfuming said sanitary fixture. 
ispiranje tog sredstva tekućom vodom za čišćenje i/ili dezinfekciju i/ili parfimiranje sanitarija.
The method according to claim 1, wherein the mutant spr gene encodes an spr protein having the mutation H145A, according to the amino acid sequence of SEQ ID NO:21. 
Postupak prema patentnom zahtjevu 1, naznačen time da mutirani spr gen kodira spr protein koji ima mutaciju H145A, sukladno aminokiselinskoj sekvenci SEK ID NO: 21.
In a particularly preferred embodiment of the invention, the outer diameter of the outer pipe is greater than 60.3 mm, that is to say, it is suitable for loads of more than 30 kN. 
Vanjska cijev u skladu s patentnim zahtjevom 1, naznačena time što je vanjski promjer vanjske cijevi (12) veći od 60,3 mm.
A dry granulated composition comprising greater than about 75% by weight emtricitabine and tenofovir DF, and which contains less than about 15% by weight of a eutectic mixture of emtricitabine and tenofovir DF. 
. Suha granulirana kompozicija naznačena time što sadrži više od oko 75 težinskih % emtricitabina i tenofovira DF, i koja sadrži manje od oko 15 težinskih % eutektičke smjese emtricitabina i tenofovira DF.
a termination signal. A recombinant vector according to claim 9, wherein said recombinant vector is capable of being replicated, transcribed, translated and expressed in a unicellular organism. 
Rekombinantni vektor prema patentnom zahtjevu 7, naznačen time da je navedeni rekombinantni vektor u stanju replicirati se, transkribirati, prevesti i eksprimirati se u jednostaničnom organizmu.
Thus, the base unit can be formed in a thinner, weaker and/or less costly material. 
Tako se osnovnu jedinicu može izraditi tanjom, slabijom i/ili od jeftinijeg materijala.
heating the cell lysate to 65°C for 30 to 120 minutes; 
(b) grijanju staničnog lizata do 65 *C 30 do 120 minuta;
The method of para 1, wherein said parent bacterial strain is selected from Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, and Oenococcus. 
Postupak prema zahtjevu 1, naznačen time da je navedeni matični bakterijski soj odabran od bakterija Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, = Listeria, - Agrobacterium, = Staphylococcus, = Streptococcus, = Enterococcus, = Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Ricketisia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, te Oenococcus.
An oral pharmaceutical tablet according to claim 1, wherein the pH-dependent release polymer is present in an amount from 15% to 75% by weight of the outer cover layer of the tablet. 
Oralna farmaceutska tableta u skladu s patentnim zahtjevom 1, naznačena time što pH-ovisni polimer za otpuštanje čini. količinski, od 15%) do 75%0, težinski, vanjskog pokrovnog sloja tablete.
taking at least two aliquots from said at least one initial sample; 
uzimanje najmanje dva alikvota iz uzorka;
Figure 1 schematically shows a casting and in-line rolling plant of the thin-slab type, particularly suitable for manufacturing steel strips according to the invention; 
Slika 1 shematski prikazuje postrojenje za lijevanje i linijsko valjanje po tipu tankog sloja, koja je posebno pogodna za proizvodnju čeličnih traka prema izumu;
According to a preferred embodiment of the present invention at least one fragment is derived from amino acid residues 150 to 170 and at least one fragment is derived from amino acid residues 205 to 225 of PCSK9 (SEQ ID No. 9). 
SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 205 do 225 od PCSKO u skladu sa SEQ ID NO:9.
the serine at position 129, 136 and 139 and the threonine at position 133 and 135 are replaced with an alanine, or 
serin na položaju 129, 136 i 139 i treonin na položaju 133 i 135 su zamijenjeni sa alaninom, ili
The process according to the invention, the block of wood being obtained according to the invention, and the veneer being obtained according to the invention have a series of particular advantages. 
Postupak koji je u skladu s ovim izumom i furnir koji je dobiven u skladu s ovim izumom imaju niz posebnih prednosti.
applying pressure to the peripheral flange to seal the lidding film to the sealable container. A process according to claim 23, wherein pressure is applied to the peripheral flange at a pressure of from 30 psi to 180 psi for a period of time of from 0.5 seconds to 5 seconds, preferably 110 psi for 1 second. 
Postupak prema patentnom zahtjevu 21, pri čemu se pritisak primjenjuje na obod pod tlakom od 206,84 KPa do 1241,06 KPa (30 psi do 180 psi) u periodu od 0,5 sekundi do 5 sekundi, poželjno 758,42 KPa (110 psi) u trajanju 1 sekunda.
For example compound of formula (V), when m and o represent 2, p represents 2 and q represents 0, may be prepared according to the method defined in scheme 3 and starting from compound (VI), wherein R4 is as defined for formula (I). 
Kao primjer, spoj formule (V), kada m i o predstavljaju 2, p znači 2, a q znači 0, može se dobiti postupkom definiranim u Shemi 3, počevši od spoja (VI), gdje R4 je definiran kao za formulu (1).
subjecting the cellulose-containing liquid phase to a cellulose spinning process to produce cellulose fibers, wherein the textile is treated with a biocatalytical or chemical solubilisation enhancer before or during the dissolution step (a) to bring the degree of polymerisation of cellulose in the range 200-1200 as measured according to ASTM D1795. 
(c) odvajanje tekuće faze koja sadrži celulozu od sintetičkih vlakana celuloze da bi se proizvela vlakna celuloze, gdje se tekstil obrađuje s biokatalitičkim ili kemijskim pojačivačem otapanja prije ili tijekom koraka otapanja (a) kako bi se stupanj polimerizacije celuloze u rasponu 200-1200 izmjerio prema ASTM D1795.
wherein substituents on the optionally substituted aryl group, optionally substituted aralkyl group, optionally substituted heteroaryl group, and optionally substituted heteroarylalkyl group are selected from: 
gdje su zamjene za po izboru supstituiranu aril grupu, po izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, i po izboru supstituiranu heteroarilalkil grupu izabrane iz:
When it became possible the product was granulated through a sieve of 3x3 mm and through a sieve of 1.2x1.2 mm (in process control, loss on drying LOD 24.3 %). 
Kada je postalo moguće, produkt je granuliran kroz sito dimenzija 3 X 3 mm 1 kroz sito dimenzija 1,2 x 1,2 mm (u kontroliranom postupku, gubitak tijekom sušenja LOD 24,3 %).
In all methods according to the invention it is preferred that the (±)-A9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema zahtjevima 1 do 5, naznačen time da (+)-A'-tetrahidrokanabinol sadrži najmanje oko 95% težinski, poželjno najmanje oko 98% težinski i još poželjnije najmanje oko 99% težinski trans-(-)-A*- tetrahidrokanabinola i trans-(+)-A*-tetrahidrokanabinola bazirano na ukupnoj količini kanabinoida.
p is 1. In another aspect, the present invention provides compounds of formula (I) in free or salt form, wherein 
U drugom obliku, predloženi izum osigurava spojeve formule (1) u slobodnom obliku ili u obliku soli, u kojoj formuli
X1, X2, X3 and X4 independently represent a hydrogen atom, a lipophilic moiety, a phenyl group, a lower alkyl, alkaryl or aralkyl group, or a cationic group of the following formula; 
X,, X2, X3 i X, neovisno predstavlja atom vodika, lipofilni dio, fenilnu skupinu, nižu alkil, alkaril ili aralkil skupinu, ili kationsku skupinu sa slijedećom formulom;
An antibody or a functional fragment thereof that specifically binds human sclerostin, wherein the antibody or functional fragment thereof comprises six CDRs with the following amino acid sequences: HCDR1 with SEQ ID NO: 26, HCDR2 with SEQ ID NO: 27, HCDR3 with SEQ ID NO: 28, LCDR1 with SEQ ID NO: 29, LCDR2 with SEQ ID NO: 30 and LCDR3 with SEQ ID NO: 31. 
Protutijelo, ili njegov funkcionalni fragment, koje se specifično veže na ljudski sklerostin, naznačeno time što protutijelo, ili njegov funkcionalni fragment, sadrži šest CDR-a, čiji su sljedeći aminokiselinski sljedovi: HCDR1, sa SEQ ID NO: 26, HCDR2, sa SEQ ID NO: 27, HCDR3, sa SEQ ID NO: 28, LCDR1, sa SEQ ID NO: 29, LCDR2, sa SEQ ID NO: 30, te LCDR3, sa SEQ ID NO: 31.
The organic partition was then washed with brine and dried over sodium sulfate before evaporating to dryness. 
Organski dio je tada bio ispran sa slanom vodom i osušen iznad natrij sulfata prije uparavanja do suhoće.